Skip to main content
ASRAFALL25 Main banner
Icon Legend
Presentation Icons
Ticket Required
Ticket Required

ePosters

(EXP-04) - Exhibit Hall ePosters - Screen 08

An Assessment of Early Suzetrigine Utilization in Real-World Settings

Friday, November 14, 2025
10:17 AM - 10:25 AM CT
Location: Griffin Hall - Screen 08
Introduction: Acute pain is a pervasive source of suffering that occurs suddenly, and can last up to 3 months.1 An estimated 80 million people are prescribed medication for acute pain annually in the United States, including analgesics such as nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and opioids.2 NSAIDs and acetaminophen have well-characterized safety risks and may not be effective for severe pain. Opioids are effective for moderate-to-severe pain but have safety concerns and carry risk of addiction.3 Despite treatment, many patients with moderate-to-severe acute pain experience inadequate pain control due to the limitations of these therapies.4

Suzetrigine is a novel oral, highly-selective voltage-gated sodium channel 1.8 (Nav1.8) pain signal inhibitor approved in the United States for the management of moderate-to-severe acute pain in adults.5 There is limited evidence to date on real-world utilization of suzetrigine; this analysis aims to describe the initial clinical utilization of this novel therapeutic agent.

    Co-Author(s)

  • VD

    Vinod Dasa, MD

    Vice Chair and Professor Orthopedic Surgery
    Department of Orthopedic Surgery, Louisiana State University Health Sciences Center, United States

    • Presenting Author(s)

  • SK

    Scott J. Keating, MSc

    Associate Director, Health Economics & Outcomes Research
    Vertex Pharmaceuticals Incorporated, United States

    • Co-Author(s)

  • MP

    Moeen Panni, MD

    Executive Medical Director & Global Medical Lead - Pain
    Vertex Pharmaceuticals Incorporated, United States

  • JM

    Jaideep Mehta, MD

    Medical Director Strategy
    Vertex Pharmaceuticals Incorporated, United States

  • NP

    Nicole Princic, MS

    Practice Leader
    Merative, United States

  • MM

    Meghan Moynihan, PhD

    Research Analyst Lead
    Merative, United States

    • Submitting Author(s)

  • AM

    Ann Menzie, MS

    Senior Director, Health Economics and Outcomes Research
    Vertex Pharmaceuticals Incorporated, United States